Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib

Ruxolitinib is a selective JAK1/2 inhibitor that is widely used for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis and polycythemia vera (PV). Despite its clinical efficacy for MPNs, ruxolitinib possesses immunosuppressive properties that potentially increase the risks...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Infect Drug Resist
Päätekijät: Sakiyama, Emiko, Chinen, Yoshiaki, Tsukamoto, Taku, Takimoto-Shimomura, Tomoko, Kuwahara-Ota, Saeko, Matsumura-Kimoto, Yayoi, Shimura, Yuji, Kobayashi, Tsutomu, Horiike, Shigeo, Kuroda, Junya
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Dove 2020
Aiheet:
Case Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7152536/
https://ncbi.nlm.nih.gov/pubmed/32308443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IDR.S249030
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia